Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 47Leukemia, Myeloid, Acute 25Recurrence 21Lymphoma, Large B-Cell, Diffuse 13Sarcoma 9Lymphoma 6Neoplasms, Plasma Cell 5Neoplasm Metastasis 5Glioblastoma 5Endometrial Neoplasms 5Ovarian Neoplasms 4Neurofibrosarcoma 4Neoplasms 4Melanoma 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Liposarcoma 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Waldenstrom Macroglobulinemia 2Thymoma 2Sarcoma, Alveolar Soft Part 2Rhabdoid Tumor 2

Interventions

Cisplatin 12Everolimus 10Nivolumab 8Etoposide 8Temozolomide 6Carboplatin 6atezolizumab 5Irinotecan 5Ipilimumab 5Fluorouracil 5Bevacizumab 5pembrolizumab 4lutetium Lu 177 dotatate 4Capecitabine 4avelumab 3Paclitaxel 3IFL protocol 3surufatinib 2sintilimab 2gallium Ga 68 dotatate 2dostarlimab 2cabozantinib 2belinostat 2azaspirane 2Topotecan 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × selinexor × Clear all
NCT02250885 2019-09-17

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Gabrail Cancer Center Research

Phase 2 Completed
14 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡